iRhythm Holdings Completes $237.5M Vital Connect Deal to Expand Cardiac Platform

Key numbers

Deal value	$238M
Share of market cap	6.5%
Share of annual revenue	31.8%

Key highlights

• Total purchase consideration of $237.5 million paid entirely in cash
• Expansion into Mobile Cardiac Telemetry (MCT) and hospital-to-home monitoring
• VitalConnect platform supports monitoring of up to 11 physiological parameters
• Acquisition expected to accelerate iRhythm revenue growth beginning in 2027
• Management reaffirmed a 15% adjusted EBITDA margin target for fiscal year 2027

What Is the Deal?

iRhythm Holdings, Inc. (NASDAQ: IRTC) officially closed its acquisition of Vital Connect, Inc. on October 5, 2026. The transaction was valued at $237.5 million in cash, which iRhythm funded through its existing balance sheet reserves. Following the close, Vital Connect became a direct wholly owned subsidiary of iRhythm Technologies, Inc. and an indirect subsidiary of the parent holding company. This strategic acquisition integrates VitalConnect's wearable biosensor technology into iRhythm’s established cardiac monitoring ecosystem, specifically targeting the high-growth mobile cardiac telemetry market. The deal consolidates two leaders in ambulatory cardiac intelligence to offer a unified, end-to-end clinical service for healthcare providers.

Strategic Rationale

The acquisition represents a major step in iRhythm's evolution into a multi-vitals monitoring company. VitalConnect’s platform is distinguished by its ability to monitor 11 different physiological parameters, including heart rate, respiratory rate, and skin temperature, over a 30-day period. By incorporating these features, iRhythm can now offer clinicians four-in-one functionality and live 'look-in' capabilities that were previously outside its core ambulatory patch portfolio. This expansion allows the company to serve patients across a broader range of settings, including inpatient facilities, remote monitoring environments, and the emerging hospital-to-home care model, thereby significantly increasing its total addressable market in the medical device sector.

Financial Context & Outlook

• Expected to enhance iRhythm's total revenue growth rate starting in the 2027 fiscal year
• Preserves the existing long-term target of 15% adjusted EBITDA margin for 2027
• Leverages iRhythm's commercial scale and health system relationships to accelerate VitalConnect growth
• Integration focuses on combining data analytics and workflow capabilities to improve clinician solutions
• Transaction provides immediate entry into the Mobile Cardiac Telemetry (MCT) service segment

Down 2.4% since our story on 5 Oct: $110.37 when we broke it → $107.71 at the close on 13 Oct. Daily closing prices. Source: Yahoo Finance.

Show the prices

14 Sep	$114.72
15 Sep	$111.88
16 Sep	$111.82
17 Sep	$111.75
18 Sep	$109.33
21 Sep	$110.38
22 Sep	$110.53
23 Sep	$111.75
24 Sep	$110.80
25 Sep	$110.38
28 Sep	$112.60
29 Sep	$114.22
30 Sep	$113.66
1 Oct	$111.05
2 Oct	$110.37
5 Oct	$109.09
6 Oct	$107.20
7 Oct	$104.99
8 Oct	$102.60
9 Oct	$106.70
12 Oct	$106.68
13 Oct	$107.71

Management Perspective

“VitalConnect brings complementary mobile cardiac telemetry (MCT), multi-vitals and monitoring capabilities to iRhythm’s established end-to-end cardiac monitoring service. Together, we can offer clinicians greater choice, serve more patients and customers across the continuum of care, and deepen customer relationships.”

Management commentary

“Joining iRhythm creates an opportunity to extend the reach and impact of VitalConnect’s technology. By bringing together what our team has built with iRhythm’s scale, clinical expertise and customer reach, we believe we can accelerate the growth of our platform, expand access to our technology and create even greater value for clinicians and patients.”

iRhythm Holdings, Inc. · financial snapshot

Share price	$110.37
Market cap	$3.6B
Revenue (annual)	$747M
1-month price change	-9.79%
Sector	HealthcareMedical Devices

Reference market data from a third-party provider, as of the story. Not a valuation or a recommendation.